Recently, we and others have demonstrated that inhibition of BRD4 by its inhibitor (JQ1) significantly suppresses cancer cell growth by triggering cell apoptosis and sensitizes lung cancer cells to radiotherapy.[14] In this study, dBET6, a more potent BRD4 degrader developed from its predecessors dBET1 and JQ1,[13] was selected to prepare nanoparticles aiming to increase therapeutic efficacy in lung cancer. The gene discussed is BRD4; the disease is lung cancer.